Serina Therapeutics appoints Farrell Simon to Board of Directors

Serina Therapeutics, Inc.

Farrell Simon appointed to Serina's Board effective July 22, 2026; will serve on Audit and Compensation Committees.
Simon is Chief Commercial Officer at Trevi Therapeutics (TRVI), helped raise over $400M from top-tier investors.
Previously spent a decade at Pfizer in senior commercial and strategic roles.
Serina's SER-252 Phase 1b registrational study is double-blind, placebo-controlled, with single and multiple ascending doses in Parkinson's patients.
Simon's experience in commercial strategy and business development expected to support Serina's POZ platform and SER-252 development.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Farrell Simon

Member of the Board of Directors

SER · Serina Therapeutics, Inc.

Effective: 2026-07-22
Filed: July 22, 2026, 5:03 PM ET

On July 22, 2026, Serina Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Farrell Simon, Pharm. D., to the Company’s Board of Directors, effective July 22, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Farrell Simon was appointed as Member of the Board of Directors at Serina Therapeutics, Inc..

Action: appointed
Role: Member of the Board of Directors

Exact text from the filing

On July 22, 2026, Serina Therapeutics, Inc. (the “Company”) issued a press release announcing the appointment of Farrell Simon, Pharm. D., to the Company’s Board of Directors, effective July 22, 2026.

View on SEC.gov

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-26-000043

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.